

PER® Organic Social Post Rewrites, April 2020

Saturday, April 25

Twitter 1 PM

For oncologists on the frontlines of patient care, #COVID19 has altered day-to-day practices. Yet patients with cancer still need the necessary care, and clinical trials must go on. Read the full article → <https://bit.ly/2XRCxwT> @TargetedOnc

LinkedIn 7 AM

As the #COVID19 pandemic evolves, many companies and researchers at the forefront of proteomics technology have shifted their focus from immune-oncology to understanding how patients' immune systems respond to the virus. Read about the new research focus → <https://bit.ly/2VmAiK1> @GenomeWeb

Twitter 6 PM

In a partnership between public and private entities, a new initiative, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), aims to make efficient use of NIH funding and its clinical trial networks. Learn more → <https://bit.ly/2z8ERPj> @ScienceMagazine

Facebook 1 PM

"As the number of confirmed cases of COVID-19 surges past 2.2 million globally and deaths surpass 150,000, clinicians and pathologists are struggling to understand the damage wrought by the coronavirus as it tears through the body." Read the article → <https://bit.ly/2XNR8D2> @ScienceMagazine

Sunday, April 26

LinkedIn 9 AM

Deliver higher-value care by utilizing the data in front of you. Learn about a tool that offers real-time clinical and financial data at the point of care → <https://bit.ly/3cwmEtG> @Healthcare Finance News

Twitter 1 PM

Results of a large, multicenter clinical trial showed reduced lung damage in rhesus macaques infected with SARS-CoV-2. "The study was designed to follow dosing and treatment procedures used for hospitalized #COVID19 patients being administered remdesivir." Read about the @NIH trial → <https://bit.ly/2XPcQgC>

Facebook 3 PM

Results of a large, multicenter clinical trial showed reduced lung damage in rhesus macaques infected with SARS-CoV-2. "The study was designed to follow dosing and treatment procedures used for hospitalized #COVID19 patients being administered remdesivir." Read about the @nih.gov trial → <https://bit.ly/2XPcQgC>

Monday, April 27

Twitter 10:45

The ABCD study—the largest long-term study of the adolescent brain ever conducted in the U.S. —will help scientists learn more about "what enhances or disrupts a young person's life trajectory." Learn more → <https://bit.ly/34M5OUO> @HITAnalytics

Twitter 4 PM

The @US_FDA remains committed to the treatment of cancer, recently granting accelerated approval to Pemazyre (pemigatinib). It is the first treatment approved for adults with certain types of previously treated, advanced #cholangiocarcinoma. Learn more → <https://bit.ly/2VMcwGu>

Facebook 1 PM

The ABCD study—the largest long-term study of the adolescent brain ever conducted in the U.S. —will help scientists learn more about “what enhances or disrupts a young person’s life trajectory.” Learn more → <https://bit.ly/34M5OUO>

Tuesday, April 28

Twitter 10 AM

Institutions want to learn more about #COVID19 in #cancer patients, and are eager to participate NCI’s new nationwide, longitudinal cohort. Learn more → <https://bit.ly/2KgSOgr> @TheCancerLetter

Twitter 1 PM

More than 1,040 sites and 950 physician investigators nationwide have signed on to help facilitate a new @US_FDA initiative to collect the plasma of those who have recovered from #COVID19. Learn more → <https://bit.ly/2z8jPAo>

LinkedIn 4 PM

More than 1,040 sites and 950 physician investigators nationwide have signed on to help facilitate a new @FDA initiative to collect the plasma of those who have recovered from #COVID19. Learn more → <https://bit.ly/2z8jPAo>

Wednesday, April 29

Twitter 10:30 AM

Our knowledge is growing every day on how to treat #COVID19. Learn about the most promising treatments → <https://bit.ly/3anm5k8> @sciam

LinkedIn 12 PM

Results of a recent study show that immunotherapy can help slow the progression of cancer in patients with metastatic urothelial cancer. “Treatment with pembrolizumab via switch maintenance immunotherapy led to further objective responses among patients who achieved at least stable disease with chemotherapy, and prolonged progression-free survival among the patient population studied.” Learn more about the study → <https://bit.ly/3cBwfzr> @Cancer Network

Twitter 6 PM

A recent study published in @JOP ASCO suggests the use of switch maintenance immunotherapy may become the standard of care for metastatic urothelial cancer. <https://bit.ly/3cBwfzr> @CancerNetwrk

Facebook 4 PM

Are you behind the curve? A clinical pharmacist relates in detail how he has been preparing for the peak of #COVID19. Watch the video → <https://bit.ly/2RRUstb> @ContagionLive

Thursday, April 30

Twitter 11 AM

@DrSteveMartin shares his insights with the oncology community on the role of adaptability during the #COVID19 pandemic. @OncNursingNews @EinsteinMed @MontefioreNYC @IASLC <https://bit.ly/2VjcFBW>